Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aviron -- Ignore unavailable to you. Want to Upgrade?

To: s jones who wrote (238)	5/30/1998 8:21:00 PM
From: SJS	Respond to of 645

Sounds like Relenza is a competitor to FluMist. Right? How do you compare their progress for acceptance with Aviron? Are they ahead of Aviron?

To: s jones who wrote (238)	5/31/1998 1:16:00 PM
From: Dennis	Read Replies (1) \| Respond to of 645

Hello, seems like Biota has a completely different product than AVIR. The patient already has the flu , is then told which kind and then is given medicine. Seems like the patient will be pretty sick by then . Also seems like the patient would have spread the virus to everyone he or she hangs with. Avir does the opposite. They prevent you , or at least try, from getting the flu AND spreading it !!! Why not buy both stocks and cover all the bases. :o) "We expect that it will become an effective tool in quickly identifying patients with influenza, who can then be treated with the influenza therapy, Relenza, when it becomes available." (from press release) IF AVIR is successful Biota won't be necessary.